Article
A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels.
Acta gastro-enterologica Belgica - 1 Jan 2000
Gerkens Sophie, Nechelput Myriam, Annemans Lieven, Peraux Bénédict, Beguin Claire, Horsmans Yves
Abstract excerpt
BACKGROUND AND STUDY AIMS: The treatment of patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels is still under discussion and the cost-effectiveness of such strategy is unknown. The objective of this study was to estimate the cost-effectiveness of their treatment in comparison with no treatment. PATIENTS AND METHODS: The assessed treatment is composed of pegylated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.